Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies

Transplantation

Volumn 87, Issue 1, 2009, Pages 94-99

  Álvarez Márquez, Antonia ^a   Aguilera, Isabel ^a   Gentil, Miguel A ^a   Caro, José L ^a   Bernal, Gabriel ^a   Alonso, Jorge Fernández ^a   Acevedo, Maria J ^a   Cabello, Virginia ^a   Wichmann, Ingeborg ^a   Gonzalez Escribano, Maria F ^a   Núñez Roldán, Antonio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Allograft rejection; Antibody mediated rejection; C4d; GSTT1; MICA

Indexed keywords

ANTIBODY; CD4 ANTIGEN; GLUTATHIONE TRANSFERASE T1 ANTIBODY; HLA A ANTIGEN; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 A ANTIBODY; UNCLASSIFIED DRUG; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; GLUTATHIONE S-TRANSFERASE T1; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE T1; HLA ANTIGEN; MHC CLASS I RELATED CHAIN A; MHC CLASS I-RELATED CHAIN A; PEPTIDE FRAGMENT;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; PLASMAPHERESIS; PRIORITY JOURNAL; SERODIAGNOSIS; ALLOTRANSPLANTATION; BIOPSY; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION;

ANTIBODIES; BIOPSY; COMPLEMENT C4B; GLUTATHIONE TRANSFERASE; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; PEPTIDE FRAGMENTS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 58949097412     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31818bd790     Document Type: Article

References (23)

1. Trpkov K, Campbell P, Pazderka F, et al. Pathologic features of acute allograft rejection associated with donor-specific antibody: Analysis using the Banff grading schema. Transplantation 1996; 61: 1586.
2. Lee PC, Terasaki PI, Takemoto SK,et al. All chronic rejection failures of kidney transplants were preceded by the developmentof HLA antibodies. Transplantation 2002; 74: 1192.
3. Terasaki P, Mizutani K. Antibody mediated rejection: Updated 2006. Clin J Am Soc Nephrol 2006; 1: 400.
4. Halloran PF. The clinical importance of alloantibody-mediated rejection. Am J Transplant 2003; 3: 639.
5. Worthington JE, Martin S, Al-Husseini D, et al. Post-transplant production of donor HLA specific antibodies as predictor of renal transplant outcome. Transplantation 2003; 75: 1034.
6. Rotman S, Collins AB, Colvin RB. C4d deposition in allograft: Current concepts and interpretation. Transplant Rev 2005; 19: 65.
7. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - An addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
8. Colvin RB. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046.
9. Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allgraft nephropathy ("CAN"). Am J Transplant 2007; 7: 518.
10. Solez K, Colvin RB, Racusen LC, et al. Banff '07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 1.
11. Opelz G. Non-HLA-transplantation immunity revealed by lymphocy-totoxic antibodies. Lancet 2005; 365: 1570.
12. Worthington JE, McEwen A, McWilliam LJ, et al. Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome. Transplantation 2007; 83: 398.
13. Zwirner NW, Marcos CY, Mirbaha F, et al. Identification of MICA as a new polymorphic alloantigen recognized byantibodies in sera of organ transplant recipients. Hum Immunol 2000; 61: 917.
14. Zou Y, Stastny P, Süsal C, et al. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357: 1293.
15. Mizutani K, Terasaki P, Bignon JD, et al. Association of kidney transplant failure and antibodies against MICA. Hum Immunol 2006; 67: 683.
16. Sumitran-Holgersson S, Wilczek HE, Holgerson J, et al. Identification of the nonclassical HLA molecules, MICA, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 2002; 74: 268.
17. Suárez-Alvarez B, Lopez-Vazquez A, Gonzalez MZ, et al. The relationship of anti-MICA antibodies and MICA expression with heart allo-graft rejection. Am J Transplant 2007; 7: 1842.
18. Aguilera I, WichmannI,Sousa JM,et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin Exp Immunol 2001; 126: 535.
19. Aguilera I, Sousa JM, Gavilan F, et al. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation. Liver Transplant 2004; 10: 1166.
20. Wichmann I,AguileraI,Sousa JM,et al. Antibodies against glutathione S-transferase T1 in non-solid organ transplanted patients. Transfusion 2006; 46: 1505.
21. Aguilera I, Wichmann I, Gentil MA, et al. Alloimmune response against donor glutathione S-transferase T1 antigen in renal transplant recipients. Am J Kidney Dis 2005; 46: 345.
22. Aguilera I, Á lvarez-Márquez A, Gentil MA, et al. Anti-glutathione S-transferase T1 antibody mediated rejection in C4d-positive renal allo-graft recipients. Nephrol Dial Transplant 2008; 23: 2393.
23. Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: A review. Mut Res 2000; 463: 247.